NZ264887A - Heterocyclic carboxamides - Google Patents

Heterocyclic carboxamides

Info

Publication number
NZ264887A
NZ264887A NZ264887A NZ26488794A NZ264887A NZ 264887 A NZ264887 A NZ 264887A NZ 264887 A NZ264887 A NZ 264887A NZ 26488794 A NZ26488794 A NZ 26488794A NZ 264887 A NZ264887 A NZ 264887A
Authority
NZ
New Zealand
Prior art keywords
group
ring
compound
stands
optionally substituted
Prior art date
Application number
NZ264887A
Other languages
English (en)
Inventor
Hideaki Natsugari
Takenori Ishimaru
Takayuki Doi
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to NZ272711A priority Critical patent/NZ272711A/xx
Publication of NZ264887A publication Critical patent/NZ264887A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ264887A 1993-11-10 1994-11-09 Heterocyclic carboxamides NZ264887A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ272711A NZ272711A (en) 1993-11-10 1995-08-03 Use of n-benzyl (or phenethyl) fused azaheterocyclic carboxamide derivatives to antagonise tachykinin receptors in mammals

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP28117893 1993-11-10
JP33748893 1993-12-28
JP3363794 1994-03-03
JP13855194 1994-06-21

Publications (1)

Publication Number Publication Date
NZ264887A true NZ264887A (en) 1996-12-20

Family

ID=27459814

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ264887A NZ264887A (en) 1993-11-10 1994-11-09 Heterocyclic carboxamides

Country Status (16)

Country Link
US (1) US5585385A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0652218B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR950014108A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1052004C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE203024T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU678295B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9404403A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2135440A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69427675T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI945281L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT68810A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL111590A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO301764B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ264887A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2135471C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW263498B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69628484T2 (de) * 1995-03-24 2004-05-19 Takeda Chemical Industries, Ltd. Zyklische Verbindungen, ihre Herstellung und ihre Verwendung als Tachykininrezeptorantagonisten
US5770590A (en) * 1995-03-24 1998-06-23 Takeda Chemical Industries, Ltd. Cyclic compounds, their prudiction and use
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU740447B2 (en) * 1997-09-23 2001-11-01 Merck & Co., Inc. Thrombin inhibitors
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
US6323214B1 (en) 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US6727258B2 (en) * 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
AU5305299A (en) * 1998-08-26 2000-03-21 Tanabe Seiyaku Co., Ltd. Naphthyridine derivatives and process for the preparation thereof
AU6228499A (en) * 1998-10-22 2000-05-08 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
WO2000074682A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Thrombin inhibitors
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
JPWO2003050123A1 (ja) * 2001-12-10 2005-04-21 杏林製薬株式会社 タキキニン受容体拮抗剤としての縮合二環式ピリジン誘導体
MXPA04006571A (es) * 2002-01-18 2004-10-04 Kyorin Seiyaku Kk Derivado de pirimidina biciclica fusionada.
WO2003068750A1 (fr) * 2002-02-13 2003-08-21 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
EP1496836B1 (en) * 2002-03-15 2008-09-24 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
WO2003080626A1 (fr) * 2002-03-26 2003-10-02 Kyorin Pharmaceutical Co., Ltd. Derive de pyrimidine bicyclique et fusionne comme antagoniste des recepteurs de tachykinine
BR0317168A (pt) * 2002-12-13 2005-11-01 Neurogen Corp Composto ou uma forma farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de reduzir condutância de cálcio de um receptor de capsaicina celular, e de inibir ligação de ligante vanilóide a um receptor de capsaicina, métodos de tratar uma condição responsiva à modulação de receptor de capsaicina, dor, coceira, tosse ou soluços, incontinência urinária, de promover perda de peso em paciente, e de determinar a presença ou ausência de receptor de capsaicina em uma amostra, preparação farmacêutica embalada, e, uso de um composto
RU2229475C1 (ru) * 2003-03-06 2004-05-27 ООО "Исследовательский институт химического разнообразия 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
JP4719152B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
US7825131B2 (en) 2003-09-23 2010-11-02 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
JPWO2005068427A1 (ja) * 2004-01-14 2007-09-06 武田薬品工業株式会社 カルボキサミド誘導体およびその用途
KR100781704B1 (ko) * 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR056048A1 (es) * 2005-09-01 2007-09-12 Tanabe Seiyaku Co Compuesto tiomorfolina y procedimiento para preparar el mismo
RU2359962C1 (ru) * 2007-12-13 2009-06-27 Общество с ограниченной ответственностью "Консорциум-ПИК" (ООО "Консорциум-ПИК") Нейротропное средство и способ его получения
RU2429230C1 (ru) * 2010-05-27 2011-09-20 Учреждение Российской академии наук Институт проблем химико-энергетических технологий Сибирского отделения РАН (ИПХЭТ СО РАН) Способ получения n-метил-4-бензилкарбамидопиридиния йодида
CA2828456C (en) * 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN102358730A (zh) * 2011-08-24 2012-02-22 济南赛文医药技术有限公司 一种小分子mek蛋白激酶抑制剂
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9663533B2 (en) 2012-11-14 2017-05-30 Glaxosmithkline Llc Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
CA2916542A1 (en) 2013-06-28 2014-12-31 Abbvie Inc. Bromodomain inhibitors
US10463655B2 (en) * 2015-03-04 2019-11-05 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
MA44674B1 (fr) 2016-04-15 2020-06-30 Abbvie Inc Inhibiteurs de bromodomaine
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
AU2021274818A1 (en) 2020-05-20 2022-09-29 AMO Ireland Azacoumarin and azathiocoumarin derivatives for use in optically active devices
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
EP4175719B1 (en) 2020-07-02 2025-05-21 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
TW205037B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
WO1991012249A1 (en) * 1990-02-10 1991-08-22 Takeda Chemical Industries, Ltd. Chromene derivatives, their production and use
US5143919A (en) * 1990-08-17 1992-09-01 Takeda Chemical Industries, Ltd. Thienopyridine derivatives and their pharmaceutical use
ATE124408T1 (de) * 1990-10-16 1995-07-15 Takeda Chemical Industries Ltd Heterozyklische aminderivate, deren herstellung und deren verwendung.
TW241258B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
DE4215588A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
US5482967A (en) * 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
JPH06298757A (ja) * 1993-04-15 1994-10-25 Kissei Pharmaceut Co Ltd ピペリジノ−3,4−ジヒドロカルボスチリル誘導体

Also Published As

Publication number Publication date
ATE203024T1 (de) 2001-07-15
IL111590A0 (en) 1995-01-24
DE69427675T2 (de) 2002-05-16
FI945281A7 (fi) 1995-05-11
RU2135471C1 (ru) 1999-08-27
FI945281L (fi) 1995-05-11
HU9403230D0 (en) 1995-01-30
US5585385A (en) 1996-12-17
AU678295B2 (en) 1997-05-22
AU7773894A (en) 1995-05-18
CA2135440A1 (en) 1995-05-11
DE69427675D1 (de) 2001-08-16
FI945281A0 (fi) 1994-11-09
CN1107476A (zh) 1995-08-30
EP0652218A1 (en) 1995-05-10
BR9404403A (pt) 1995-07-18
EP0652218B1 (en) 2001-07-11
RU94040174A (ru) 1996-10-10
KR950014108A (ko) 1995-06-15
NO944252D0 (no) 1994-11-08
NO944252L (no) 1995-05-11
TW263498B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-11-21
CN1052004C (zh) 2000-05-03
NO301764B1 (no) 1997-12-08
HUT68810A (en) 1995-05-19

Similar Documents

Publication Publication Date Title
NZ264887A (en) Heterocyclic carboxamides
KR100595740B1 (ko) Rho 키나아제 억제제를 함유하는 약제
KR100667645B1 (ko) 환상 아민 ccr3 길항제
JPH0662414B2 (ja) アリールアミドアザビシクロアルカンを含む記憶増強または記憶欠損矯正用組成物
CA2508681A1 (en) Quinoline compounds for use in mch receptor related disorders
CN107531633A (zh) 5‑芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
KR20010042739A (ko) 티에닐아졸일알콕시에탄아민, 이의 제조방법 및 이의 용도
JPH08301849A (ja) ヘテロ環化合物およびその製造法
JP2002053566A (ja) チアゾール化合物及びその医薬用途
US9018231B2 (en) Sulfone compounds as 5-HT6 receptor ligands
US9540375B2 (en) Kappa opioid receptor effectors and uses thereof
US6423714B2 (en) Cyclohexene derivatives useful as antagonists of the motilin receptor
JPS6230191B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2005118582A1 (ja) アミド化合物を含有する角膜知覚回復剤
AU755124B2 (en) Benzamide derivatives and drugs containing the same
EP0367040B1 (en) Compounds for the treatment of urinary incontinence
DK149753B (da) Analogifremgangsmaade til fremstilling af morfinderivater
IE903616A1 (en) Neuroprotectant Agents
JPH09512784A (ja) 酢酸アミド誘導体及びその製造方法
EP2346847B1 (en) Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
KR100636515B1 (ko) 신규 형태의 축합 피리다지논 화합물
JPS58109489A (ja) イミダゾベンゾジアゼピン化合物、該化合物を含有する医薬製剤及び該化合物の製造方法
WO2012033435A1 (ru) Способ, соединение, фармацевтическая композиция и лекарственное средство для восстановления утраченной памяти в норме и патологии
JPH08301871A (ja) 縮合複素環化合物およびその製造法
CA2008571A1 (en) Pyridazino[4,5-b]indolizines